Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China

BACKGROUND: In the Checkmate9ER trial, first-line treatment with nivolumab combined with cabozantinib (NI + CA) has shown efficacy for advanced renal cell carcinoma. This study aims to evaluate the impact of the health and economic outcomes of NI + CA in China. METHODS: Clinical efficacy data were d...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hao, Wang, Ye, Li, Li, Zhou, Han, Lili, Shang, Li, Liao, Yike, Shen, Aixia, Ma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490003/
https://www.ncbi.nlm.nih.gov/pubmed/36159269
http://dx.doi.org/10.3389/fpubh.2022.954264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490003/
https://www.ncbi.nlm.nih.gov/pubmed/36159269
http://dx.doi.org/10.3389/fpubh.2022.954264

Ejemplares similares